Moreover, in cardiac fibroblasts, luteolin is also anti-fibrotic through the NO-cGMP signaling pathway [242, 243]
Although the exact etiology remains unknown, current evidence points to a significant genetic component in the development and severity of FM which can be associated with a spectrum of diseases, including infections, diabetes, rheumatic diseases, and psychiatric or neurological comorbidities [6]
View the full Certificate of Analysis here: A 5mg vial can be especially useful when a laboratory wants a smaller, clearly defined format for controlled analytical work and early-stage pathway comparison
doi: 10.1007/s13679-017-0262-y
It means the FDA has not yet determined that the evidence meets the threshold for a label change
You want premium fuel, not whatever's cheapest